Updates are available Correction dated 2018-07-06
Click to view Correction: https://doi.org/10.1038/s41523-018-0069-3
-
Authors
Petkov, Valentina I
Miller, Dave P
Howlader, Nadia
Gliner, Nathan
Howe, Will
Schussler, Nicola
Cronin, Kathleen
Baehner, Frederick L
Cress, Rosemary
Deapen, Dennis
Glaser, Sally L
Hernandez, Brenda Y
Lynch, Charles F
Mueller, Lloyd
Schwartz, Ann G
Schwartz, Stephen M
Stroup, Antoinette
Sweeney, Carol https://orcid.org/0000-0003-1113-7160
Tucker, Thomas C
Ward, Kevin C
Wiggins, Charles
Wu, Xiao-Cheng
Penberthy, Lynne
Shak, Steven
- License Information
-
More Information
Article History
Received: 20 April 2016
Revised: 2 May 2016
Accepted: 13 May 2016
First Online: 8 June 2016
Change Date: 6 July 2018
Change Type: Corrigendum
Change Details: In the original version of the published Article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results <18 and 1–3 positive nodes (n = 2,617) was 1.3% (95% CI, 0.6–2.9%).” To improve clarity this statement has been replaced with “Excluding patients with micrometastatic disease, there were 2,617 patients with 1-3 positive nodes. Of these, 1,487 also had Recurrence Score results <18 with 5-year BCSM of 1.3% (95% CI, 0.6–2.9%).” The original version of the published Article also contained an error in the second sentence of the Figure 2 legend describing the mutation status of the patient population examined. The sentence in the original published version of the Article stated “Patients with HR+, HER2-positive, node-negative…” this has been changed to “Patients with HR+, HER2-negative, node-negative…”. This has been corrected in the HTML and PDF version of the Article.
Competing interests
: D.P.M., N.G., F.L.B., and S.S. are employees of Genomic Health. The remaining authors declare no conflict of interest.
